- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00144235
Pharmaton Upgrade in Improving Mental Performance and Decreasing Fatigue
A 28 Day, Randomised, Double-blind, Placebo-controlled, Single-centre Trial to Evaluate the Efficacy and Safety of Pharmaton® PHL 00749 Film Coated Tablets (G115 40 mg, Multivitamin, Multimineral + Guarana 75 mg) 1/Day p.o. in Improving Mental Performance and to Decrease Fatigue in Healthy Male and Female Subjects in Regular Employment.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a double-blind, placebo-controlled, randomised, parallel group trial in healthy male and fem ale subjects in regular employment. The duration of dosing will be 28 '(+/- 1)' days and assessments w ill be made on two visits (visits 2 and 3) with a training on the CDR system at the screening visit.
The subjects will receive one bottle with 35 tablets [of either Ginseng G115 40 mg, multivitamin, mu ltimineral '+' Paullinia cupana extract PC102 75 mg (Guarana) or placebo] from the pharmacy at the in vestigational site. The subjects should take the study drug from day 0 to day 28 '(+/- 1)' Subjects will be assigned to one of the two treatment groups randomly. The allocation ratio is 2:1..
Study Hypothesis:
H0: No difference exists between the treatment and the placebo groups in terms o f baseline-adjusted change in Power of Attention after 28 days and averaged over 4 and 6 hour time point. H1: A difference exists between the treatment and the placebo groups in terms of baseline-adjusted change in Power of Attention after 28 days and averaged over 4 and 6 hour time point. The null and alternative hypotheses for the secondary endpoints are set up accor dingly. The statistical testing will be carried out at the 0.05 level of signifi cance. The test will be performed two-tailed.
Comparison(s):
The comparator is a matching placebo film-coated tablet without active ingredien ts.
Study Type
Enrollment
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Aldershot, United Kingdom, GU11 3RB
- Boehringer Ingelheim Investigational Site
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
INCLUSION CRITERIA Healthy male and female subjects in regular employment, aged between 20 and 50 y ears. Subjects who give written informed consent in accordance with GCP and local legi slation.
EXCLUSION CRITERIA Subjects who present with clinical depression. Subjects showing evidence of dementia. Clinically relevant abnormalities in medical history or examination. Subjects who have participated in a clinical study within 3 months prior to the start of the study. History of drug and/or alcohol abuse. Subjects who smoke more than 10 cigarettes per day. Subjects who in the opinion of the Investigator are heavy users of other tobacco or nicotine products (e.g. snuff, chewing tobacco, nicotine patches, nicotine g um, etc.). Subjects who have a history of food and/or drug allergies relevant to the study compound. Clinically relevant deviation from normal of any finding during pre-study medica l screening. Subjects who are unable to perform the cognitive tests. Subjects currently taking a cognition enhancing substance, including any Ginkgo, ginseng or guarana product. Any subject regularly taking a medication who might stop doing so at some time d uring the active dosing phase. Pregnant or lactating women or female subjects of child-bearing potential not us ing adequate means of birth control (condoms, contraceptive pills, IUDs, sterili sation). Subjects already taking other multi-vitamin products during the last 2 weeks. Healthy subjects who are regularly taking drugs which act on the Central Nervous System (CNS).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: DOUBLE
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Primary Endpoint: The baseline (day 0 pre-dose) adjusted change in the CDR Factor, Power of Attention, at day 28 averaged over the 4 and 6 hour post-dosing time points.
Time Frame: 28 days
|
28 days
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The baseline (day 0 pre dose) adjusted change in the CDR Factor, Power of Attention, at day 0 averaged over the 4 and 6 hour post dosing time points.
Time Frame: 28 days
|
28 days
|
The baseline (day 0 pre-dose) adjusted change scores at day 28 in the CDR factors: Continuity of Attention, Quality of Episodic Secondary Memory, Speed of Memory and Quality of Working Memory
Time Frame: 28 days
|
28 days
|
The baseline (day 0 pre-dose) adjusted change scores at day 28 in the individual CDR tests.
Time Frame: 28 days
|
28 days
|
The baseline (day 0 pre-dose) adjusted change scores at day 0 in the CDR factors: Continuity of Attention, Quality of Episodic Secondary Memory, Speed of Memory and Quality of Working Memory.
Time Frame: 28 days
|
28 days
|
The baseline (day 0 pre-dose) adjusted change scores at day 0 in the individual CDR tests
Time Frame: 28 days
|
28 days
|
The day 0 pre-dose adjusted change scores at day 28 in the CDR factors: DailyStressInventory,Pro- and RetrospectiveMemoryQuest,CognitiveFailures quest, St. Mary's HospitalSleep Quest,SpielbergerStateTraitAnxiety Quest,PsychologicalGeneralWell-Being Quest
Time Frame: 28 days
|
28 days
|
Incidence of all adverse events
Time Frame: 28 days
|
28 days
|
Vital signs (BP and HR)
Time Frame: 28 days
|
28 days
|
Overall tolerability assessment by the subject and investigator
Time Frame: 28 days
|
28 days
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Boehringer Ingelheim Study Coordinator, Pharmaton
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 1232.1
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Mental Fatigue
-
Bakulev Scientific Center of Cardiovascular SurgeryFoundation for the Support of Physical Culture and Sports BECOME A CHAMPION; Autonomous Non-Profit organization of additional education sports school BECOME A CHAMPIONNot yet recruitingEfficacy, Self | Fatigue, Mental | Fatigue; Muscle, Heart | Fatigue; CombatRussian Federation
-
Universita di VeronaUniversity of Southern CaliforniaCompletedDiet, Healthy | Fasting | Fatigue, Mental | Fatigue; Muscle, HeartItaly
-
Supplement Formulators, Inc.Completed
-
PepsiCo Global R&DCompletedMotivation | Mood | Cognitive Performance | Fatigue, Mental | AlertnessUnited States
-
Vedic Lifesciences Pvt. Ltd.CompletedAlert Fatigue, Health PersonnelIndia
-
University GhentCompletedMental Fatigue | Muscle Fatigue | Event-related PotentialsBelgium
-
Lancaster UniversityMedtronic; East Lancashire Hospitals NHS Trust; KARL STORZ Endoscopy-America,... and other collaboratorsCompletedFatigue | Surgery | Fatigue, Mental | Muscle Strain | Training Group, SensitivityUnited Kingdom
-
Eskisehir Osmangazi UniversityRecruitingStress Perception, Psychological Resilience, Compassion FatigueTurkey
-
National Taiwan Normal UniversityCompletedMental FatigueTaiwan
-
University of GeorgiaThe Hershey CompanyCompleted
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States